ELI LILLY AND COMPANY Stock Repurchase Program, Remaining Authorized Repurchase Amount (Deprecated 2014-01-31)
ELI LILLY AND COMPANY (LLY) reported Stock Repurchase Program, Remaining Authorized Repurchase Amount (Deprecated 2014-01-31) of $419.20 million for the 9-month period ending 2012-09-30, per its 10-Q filed 2012-10-26.
Discontinued › Notes › Equity
us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount · last filed 2012-10-26
- ELI LILLY AND COMPANY stock repurchase program, remaining authorized repurchase amount (deprecated 2014-01-31) for the quarter ending 2012-09-30 was $0.00.
| Period end | Stock Repurchase Program, Remaining Authorized Repurchase Amount (Deprecated 2014-01-31) 3 month | Stock Repurchase Program, Remaining Authorized Repurchase Amount (Deprecated 2014-01-31) 6 month | Stock Repurchase Program, Remaining Authorized Repurchase Amount (Deprecated 2014-01-31) 9 month |
|---|---|---|---|
| 2012-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2012-10-26 | $419.20M 10-Q · filed 2012-10-26 | |
| 2012-06-30 | $419.20M 10-Q · filed 2012-07-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |